On Friday, Arcus Biosciences Inc (NYSE: RCUS) was -4.83% drop from the session before settling in for the closing price of $14.92. A 52-week range for RCUS has been $13.52 – $20.31.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 186.11%. When this article was written, the company’s average yearly earnings per share was at 17.81%. With a float of $49.27 million, this company’s outstanding shares have now reached $91.50 million.
Let’s determine the extent of company efficiency that accounts for 577 employees. In terms of profitability, gross margin is 96.2%, operating margin of -120.91%, and the pretax margin is -102.28%.
Arcus Biosciences Inc (RCUS) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Arcus Biosciences Inc stocks. The insider ownership of Arcus Biosciences Inc is 46.16%, while institutional ownership is 54.53%. The most recent insider transaction that took place on Dec 31 ’24, was worth 53,910. In this transaction Chief Financial Officer of this company sold 3,594 shares at a rate of $15.00, taking the stock ownership to the 60,138 shares. Before that another transaction happened on Dec 31 ’24, when Company’s Officer proposed sale 3,594 for $15.00, making the entire transaction worth $53,910.
Arcus Biosciences Inc (RCUS) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.06 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 17.81% per share during the next fiscal year.
Arcus Biosciences Inc (NYSE: RCUS) Trading Performance Indicators
You can see what Arcus Biosciences Inc (RCUS) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 5.23. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.94.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.15, a number that is poised to hit -1.25 in the next quarter and is forecasted to reach -4.33 in one year’s time.
Technical Analysis of Arcus Biosciences Inc (RCUS)
Looking closely at Arcus Biosciences Inc (NYSE: RCUS), its last 5-days average volume was 0.53 million, which is a drop from its year-to-date volume of 0.54 million. As of the previous 9 days, the stock’s Stochastic %D was 16.85%. Additionally, its Average True Range was 0.78.
During the past 100 days, Arcus Biosciences Inc’s (RCUS) raw stochastic average was set at 3.24%, which indicates a significant decrease from 7.84% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 34.73% in the past 14 days, which was lower than the 54.14% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $15.83, while its 200-day Moving Average is $16.07. However, in the short run, Arcus Biosciences Inc’s stock first resistance to watch stands at $14.60. Second resistance stands at $15.00. The third major resistance level sits at $15.28. If the price goes on to break the first support level at $13.92, it is likely to go to the next support level at $13.64. Now, if the price goes above the second support level, the third support stands at $13.24.
Arcus Biosciences Inc (NYSE: RCUS) Key Stats
There are 91,512K outstanding shares of the company, which has a market capitalization of 1.30 billion. As of now, sales total 117,000 K while income totals -307,000 K. Its latest quarter income was 48,000 K while its last quarter net income were -92,000 K.
